Our Centres
Our Doctors
Your state: SA |
Our Centres
Our Doctors
A/Prof Michael Ng
MBBS (Hons), FRANZCR, Radiation Oncologist
For patients/carers
For doctors
MBBS (Hons), FRANZCR, Radiation Oncologist
Locations
Clinical interests
- Genitourinary cancer
- Breast cancer
- Lung cancer
- Gastrointestinal cancer
- Lymphoma
- Myeloma
- Brain and central nervous system
- Dupuytren's disease
Languages
Fluent
- English
Conversational
- Cantonese / 廣東話
Biography
Clinical interests in prostate, breast, lung, and gastrointestinal cancers, lymphoma and stereotactic radiation therapy.
Michael is an honours graduate of Monash University Medical School. He trained as a radiation oncology registrar at the Peter MacCallum Cancer Centre and spent his fellowship year overseas at the Royal Marsden Hospital, United Kingdom. He returned to Australia and worked as a staff specialist at the Peter MacCallum Cancer Centre in head and neck and gastrointestinal cancers.
He has been working with GenesisCare since 2009 as a general oncologist, with clinical interests in breast, prostate, gastrointestinal and lung cancer.
Michael is the head of the stereotactic radiation therapy service at GenesisCare in Victoria. He has previously been radiotherapy chair of EviQ cancer guidelines (Cancer Institute NSW), and since 2017 is an advisor to the federal government Department of Health on the Medical Services Advisory Committee (MSAC) which appraises new medical services proposed for public funding.
More information
Michael's research interests include prostate cancer management.
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- American Society for Radiation Oncology (ASTRO)
- European Society for Radiotherapy and Oncology (ESTRO)
- Australasian Gastro-Intestinal Trials Group (AGITG)
- Schupak, I., Chao, M., Guerrieri, M., Ho, H., Udovicich, C., Ong, W. L., Starmans, M., Tacey, M., Foroudi, F., Joon, D. L., Ng, M., & al. (2025). Stereotactic ablative body radiotherapy for PSMA-PET/CT staged, oligometastatic prostate cancer: A multi-centre study. Radiotherapy and Oncology, 214, 111219. https://doi.org/10.1016/j.radonc.2025.111219
- Wegener, E., Ng, M., Guerrieri, M., Showalter, T. N., Leon, J., Ramani, S., Dreosti, M., Lim, T., Wong, B., Chao, M., Hogan, K., Raman, A., McClintock, S., Foreman, D., Brown, M., McCombie, S., McMillan, K., Beattie, K., Frydenberg, M., Wong, L. M., Hayne, D., Yaxley, J., Stricker, P., & Martin, J. (2025). A multicentre implementation trial of an artificial intelligence–driven biomarker to inform shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: The ASTuTE protocol. BMC Cancer, 25(1), 250. https://doi.org/10.1186/s12885-025-13622-1
- Ward, J., Armstrong, K., Kang, T. M.-J., Tham, J., Lin, Y.-H., Ng, M., Cheng, M., et al. (2025). A population-based analysis of the evolving management of cN1M0 prostate cancer in the PSMA-PET era. BJUI Compass, 6(7), e70059. https://doi.org/10.1002/bco2.70059
- Howell, J., Emery, J. D., Roberts, S., Thompson, A. J., Ng, M., George, J., Leggett, B. A., Tse, E., Nguyen, B., Combo, T., & Wigg, A. J. (2025). Opportunities to improve surveillance of hepatocellular carcinoma in Australia. Medical Journal of Australia, 223, 61–67. https://doi.org/10.5694/mja2.52691
- Wong, L. M., Sutherland, T., Perry, E., Tran, V., Spelman, T., Corcoran, N., Lawrentschuk, N., Woo, H., Lenaghan, D., Buchan, N., Bax, K., Symons, J., Saeed Goolam, A., Chalasani, V., Hegarty, J., Thomas, L., Christov, A., Ng, M., Khanani, H., Lee, S. F., Taubman, K., & Tarlinton, L. (2024). Fluorine-18–labelled prostate-specific membrane antigen PET/CT or MRI to diagnose and localise prostate cancer: A prospective single-arm paired comparison (PEDAL). European Urology Oncology. https://doi.org/10.1016/j.euo.2024.01.002
- Tissot, S., Wynn, J., Tran, V., Farag, M., Wong, L.-M., & Ng, M. (2023). Re-defining 18F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology. BJU International, 132, 411–419.
- Harris, N., Tan, M. Y., Ng, M., Blakey, D., Guerrieri, M., Joon, D. L., Lau, E., Foroudi, F., Armstrong, A., & Chao, M. (2022). PSMA-PET detection of unusual metastases in castrate-sensitive prostate carcinoma. Clinical Nuclear Medicine. https://doi.org/10.1097/RLU.0000000000004469
- Williams, J., Millan, K. M., Bolton, D., Tan, A., Cham, C. W., Pham, T., Pan, D., Liu, M., Chan, Y., Manohar, P., Thomas, J., Koufogiannis, G., Ho, H., Guerrieri, M., Ng, M., Boike, T., Macleod, C., Joon, D. L., Foroudi, F., & Chao, M. (2022). Hyaluronic acid rectal spacer in EBRT: Usability, safety and symmetry related to user experience. Journal of Medical Imaging and Radiation Sciences. https://doi.org/10.1016/j.jmir.2022.09.008
- Perry, E., Talwar, A., Taubman, K., Ng, M., Wong, L. M., & Sutherland, T. R. (2022). Pathological predictors of 18F-DCFPyL prostate-specific membrane antigen–positive recurrence after radical prostatectomy. BJU International, 130(Suppl 1), 28–36. https://doi.org/10.1111/bju.15724
- A.J. Costello Best Abstract Award – Australian Prostate Cancer Conference 2025: Artificial intelligence impact on decision making regarding short-term ADT prostate radiotherapy: ASTuTE trial interim results.
- Merit Award – Genitourinary ASCO Annual Meeting 2008: PSA kinetics in untreated prostate cancer: PSA doubling time versus PSA velocity. (Ng, M., Van As, N., et al.)
- Best Oral Presentation & RANZCR Varian Prize – RANZCR Annual Meeting 2004: Parotid sparing radiotherapy: Does it really reduce xerostomia? (Ng, M., Porceddu, S., et al.)
- Outstanding Achievement in Health Promotion – Victorian Health Foundation 1995: Prostate Cancer Awareness. (Ng, M., Tay, B.H., et al.)
